SCHEMBL3227030

SCHEMBL3227030

O=C(O)c1csc(Nc2cnccn2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
NAPRT Q6XQN6 1/20 0.50
HCAR2 Q8TDS4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
GAA P10253 1/20 0.45
KDR P35968 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
MC4R P32245 1/20 0.41
ADRA1A P35348 1/20 0.41
MC3R P41968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL525588 0.79 NPC1 (0.61) KDM4ENAPRTL3MBTL1RAB9ANPC1
SCHEMBL2373447 0.79 SMN1; SMN2 (0.52) RAB9AGAASMN1; SMN2POLBMEN1
SCHEMBL525526 0.75 MAPK1 (0.62) KDM4EL3MBTL1RAB9ANPC1GAA
SCHEMBL24803980 0.75 GAA (0.56) KDM4ERAB9ANPC1GAAKDR
SCHEMBL3028524 0.74 MEN1 (0.50) KDM4EL3MBTL1RAB9ANPC1SMN1; SMN2
SCHEMBL14742760 0.74 RAB9A (0.60) KDM4EL3MBTL1RAB9ANPC1GAA
SCHEMBL525280 0.74 MEN1 (0.56) KDM4EL3MBTL1RAB9ANPC1KDR
SCHEMBL525271 0.74 KDM1A (0.54) L3MBTL1RAB9ANPC1GAASMN1; SMN2
SCHEMBL5185201 0.74 L3MBTL1 (0.53) L3MBTL1RAB9ANPC1GAASMN1; SMN2
SCHEMBL29674695 0.72 HPGDS (0.53) KDM4EL3MBTL1RAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078002-B1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
US-8227605-B2 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors SCHERING CORPORATION (US) 2012-07-24 US disclosed
US-20100055090-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME LLC 2010-03-04 US disclosed
EP-2078002-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-07-15 EP disclosed
WO-2008054701-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055090-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MAPK15, CDK15, MAP3K15 KDM4E 1457/4885NAPRT 1854/4885HCAR2 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.